By Connor Hart
Shares of Curis jumped after the company released what it assessed as positive data from a study of its in-development treatment for leukemia.
The stock was up 33%, to $4.07, in midday trading Thursday. Shares ended 2024 down 73%.
The Lexington, Mass., biotech company said its treatment, emavusertib, resulted in 10 objective responses out of 19 response-evaluable patients. Six patients achieved complete remission; two achieved complete remission with either incomplete or partial hematological recovery, meaning that blood cell counts haven't fully returned to normal; and two achieved a morphologic leukemia-free state, which indicates the disappearance of leukemia cells and bone marrow recovery.
Emavusertib previously received orphan drug designation, a regulatory status granted to drugs or biologics intended to treat rare diseases or conditions, from the Food and Drug Administration for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and from the European Commission for the treatment of primary central nervous system lymphoma.
"We continue to be pleased with the monotherapy data in R/R AML patients with a FLT3 mutation and believe these data further support the exciting potential of emavusertib's novel mechanism to address a significant unmet need in patients with AML," Chief Executive James Dentzer said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 02, 2025 12:45 ET (17:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。